Navigation Links
Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
Date:12/10/2013

NEW ORLEANS, Dec. 10, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013. There were seven presentations of clinical data, of which five were oral presentations, including one "Best of ASH" presentation on Waldenstrom's macroglobulinemia (WM). In total, 33 additional pre-clinical and non-clinical presentations provided new discoveries using ibrutinib; seven of these were oral presentations. The presentations further elucidated the mechanism of action of ibrutinib and its effect in the tumor microenvironment and provided data on quality of life changes. Results covered various B-cell malignancies: chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), WM, and non-Hodgkin lymphoma (NHL).

"The breadth of data presented at ASH this year demonstrates the scientific community's interest in ibrutinib and builds on the clinical responses seen with ibrutinib as a backbone of combination therapy and as a single agent in multiple B-cell malignancies," said Jesse McGreivy, M.D., Chief Medical Officer, Pharmacyclics. "This year's data explain ibrutinib's effect on the quality of life for patients and build on impressive efficacy and safety results, independent of cytogenetic risk factors. We also now have long-term follow-up in CLL, which suggests continuation of the efficacy and a decrease in overall and severe adverse events."

Clinical Trial Presentation Highlights

Chronic Lymphocytic Leukemia

-POSTER PRESENTATION- Abstract #4163:
The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibruti
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. WuXi PharmaTech to Partner with Pharmacyclics
2. Pharmacyclics Reports Third Quarter 2013 Results
3. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
4. Pharmacyclics Reports Second Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
6. Pharmacyclics Reports First Quarter 2013 Results
7. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
8. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
9. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
10. Pharmacyclics, Inc. Prices Public Offering of Common Stock
11. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... KUALA LUMPUR, Malaysia , April 20, 2015 /PRNewswire/ ... 2015, resulting in a scarcity of opportunities for generic ... drug manufacturers in the region are looking beyond the ... the quality of existing drugs. Certain established generic manufacturers ... research and development of new molecules, although the impact ...
(Date:4/20/2015)... , April 21, 2015  Following is the ... LIFESAVING MEDICINE ... most important medicines — insulin —became available for general ... millions of people suffering from diabetes. Insulin is a ... the processing of carbohydrates in the human body. It ...
(Date:4/20/2015)... -- This report analyzes the worldwide markets for Breast Pumps ... Pumps, and Powered Breast Pumps. The report provides separate comprehensive ... Japan , Europe , ... and forecasts are provided for the period 2014 through 2020. ... Market data and analytics are derived from primary and secondary ...
Breaking Medicine Technology:Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 2Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 3Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 4Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 5U.S. Census Bureau Daily Feature for April 21 2World Breast Pumps Industry 2World Breast Pumps Industry 3World Breast Pumps Industry 4World Breast Pumps Industry 5World Breast Pumps Industry 6World Breast Pumps Industry 7World Breast Pumps Industry 8World Breast Pumps Industry 9World Breast Pumps Industry 10World Breast Pumps Industry 11World Breast Pumps Industry 12World Breast Pumps Industry 13World Breast Pumps Industry 14
... Inc. (Nasdaq: STRM ) today announced financial ... ended January 31, 2011. Highlights for the ... purchase contracts for add-on licenses with existing clients totaling ... recognized during the quarter; Company completed and ...
... N.J., April 12, 2011 Novartis Pharmaceuticals Corporation ... Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) ... treatment of patients with advanced neuroendocrine tumors (NET) ... provided after presentation of data from the everolimus ...
Cached Medicine Technology:Streamline Health® Solutions Reports Q4 Results 2Streamline Health® Solutions Reports Q4 Results 3Streamline Health® Solutions Reports Q4 Results 4Streamline Health® Solutions Reports Q4 Results 5Streamline Health® Solutions Reports Q4 Results 6Streamline Health® Solutions Reports Q4 Results 7Streamline Health® Solutions Reports Q4 Results 8Streamline Health® Solutions Reports Q4 Results 9Streamline Health® Solutions Reports Q4 Results 10Streamline Health® Solutions Reports Q4 Results 11Streamline Health® Solutions Reports Q4 Results 12Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 2Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 3Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 4Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 5Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 6Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 7Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 8Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 9Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 10
(Date:4/20/2015)... When author Faith Canter was diagnosed ... if nothing could wake her up - and she wasn’t ... are currently living with CFS. , Rather than accepting her ... Living a Life Less Toxic : The Whole Life Approach ... Happier, Healthier Life for You, Your Family and Our Planet.” ...
(Date:4/20/2015)... Heritage Woods of Centralia, a Gardant ... and Dine-and-Dash Spaghetti Dinner from 4 p.m. to 6 ... located in Centralia, Illinois, houses senior living apartments, affordable ... 55 and older. , Guests are invited to tour ... options for seniors. After the tours, they can take ...
(Date:4/20/2015)... 2015 Construction has reached completion ... Draft, an independent, nonprofit community hospital with existing ... The project was an ongoing collaboration between Timmons ... is expected to provide additional employment opportunities for ... Highway, the new facility features physician offices, a ...
(Date:4/20/2015)... April 21, 2015 Using Quality by ... Speed Production and Improve Compliance , **FDAnews Webinar**, May ... http://www.fdanews.com/qualitybydesign , The life sciences industries are ... to do more with less. Mergers, acquisitions, the ... to finds ways to speed up production while still ...
(Date:4/20/2015)... Is it possible to create measures of ... the local needs of the providers, payers and patients who ... over the past year by the Hutchinson Institute for Cancer ... Center in Seattle, Washington. , In a new commentary ... Journal of Managed Care, HICOR Director Scott Ramsey, MD, ...
Breaking Medicine News(10 mins):Health News:New book by Faith Canter offers guide to banishing toxins 2Health News:Heritage Woods of Centralia Senior Living Community to Host Open House and Spaghetti Dinner 2Health News:Augusta Health Construction Wraps Up at Stuarts Draft 2Health News:FDAnews Announces — Using Quality by Design to Improve Manufacturing: How Sponsors and CMOs Speed Production and Improve Compliance Webinar, May 7, 2015 2Health News:FDAnews Announces — Using Quality by Design to Improve Manufacturing: How Sponsors and CMOs Speed Production and Improve Compliance Webinar, May 7, 2015 3Health News:Creating Value Metrics in Cancer Care From the Bottom Up 2Health News:Creating Value Metrics in Cancer Care From the Bottom Up 3
... to a major disaster should focus on three consecutive missions: ... aid, according to research presented Sunday, Oct. 3, at the ... San Francisco. In January, within 24 hours of ... States Naval Ship (USNS) Comfort was deployed to Haiti. With ...
... was higher among adults in Puerto Rico compared to ... was lower, according to data presented at the Third ... held Sept. 30 to Oct 3, 2010. Genetic ... and other venues, providing individual access to genetic tests ...
... Hopkins Medicine, Johns Hopkins scientists have discovered a way to ... proteins in mice, a discovery that could have implications for ... such as peanuts and milk. The findings, published online ... the body could be trained to tolerate food allergies that ...
... instrument due to fly aboard NASA,s James Webb Space Telescope ... facilities at the Rutherford Appleton Laboratory (RAL) in the United ... to areas of investigation as diverse as the first light ... other stars. "The start of space simulation testing ...
... A UC Irvine infectious disease specialist has received a ... methods to prevent staph infections in people who harbor MRSA ... Agency for Healthcare Research & Quality awarded Huang the grant ... American Recovery & Reinvestment Act of 2009. CHOICE grants will ...
... Boston Medical Center (BMC) doctors have proven the ... tool that assesses the cleanliness of the colon during ... of the journal Gastrointestinal Endoscopy , demonstrates the ... to rate colon cleanliness during colonoscopy. Audrey ...
Cached Medicine News:Health News:Operation Unified Response: 3 phases of disaster care in Haiti 2Health News:Adults in Puerto Rico aware of genetic testing, but use remains low 2Health News:Johns Hopkins researchers turn off severe food allergies in mice 2Health News:NASA's Webb telescope MIRI instrument takes one step closer to space 2Health News:NASA's Webb telescope MIRI instrument takes one step closer to space 3Health News:NASA's Webb telescope MIRI instrument takes one step closer to space 4Health News:UCI gets major funding to study ways of preventing drug-resistant staph infections 2Health News:Boston Medical Center research study validates the Boston Bowel Preparation Scale 2
... SureFlex™ line of reusable and autoclavable Lithotripsy ... This revolutionary and patented termination method accepts ... In the unlikely event you do manage ... face absolutely prevents damage to your laser ...
ELVeS™ (Endo Laser Vein System) from biolitec is a versatile, easy to use & complete system that allows you to treat all conditions resulting from venous incompetence. (ELVeS has FDA clearance ...
Up-tapered output compresses NA to give low NA fiber performance on high NA fiber stock....
One piece, 100% fused silica construction offers low scatter and high efficiency...
Medicine Products: